Voronoi, Signed Contract for Technology Transfer in Targeted Therapy Research and Development
[Asia Economy Reporter Lee Jung-yoon] Voronoi announced on the 22nd that it has signed a technology licensing agreement with Voronoi Bio for the research and development of a new targeted therapy.
Hot Picks Today
Dramatic Agreement Reached on Eve of Samsung Electronics General Strike... Minister Kim Young-hoon: "Showcased Korea's Strength in Dialogue" (Update)
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, "The technology involves a targeted therapy candidate substance aimed at mutations in EGFR non-small cell lung cancer," adding, "It is planned to be developed as an oral drug with higher mutation selectivity and brain permeability compared to competing substances."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
